NUPR1 and prostate adenocarcinoma: Another study conducted the scRNA-seq on docetaxel-sensitive and -resistant variants of PRAD DU145 and PC3 cell lines, revealing NUPR1 as a mediator of PRAD drug resistance (Schnepp et al., 2020).